A detailed history of Fifth Third Bancorp transactions in Xencor Inc stock. As of the latest transaction made, Fifth Third Bancorp holds 382 shares of XNCR stock, worth $9,366. This represents 0.0% of its overall portfolio holdings.

Number of Shares
382
Previous 248 54.03%
Holding current value
$9,366
Previous $4,000 75.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$15.7 - $21.65 $2,103 - $2,901
134 Added 54.03%
382 $7,000
Q2 2024

Jul 22, 2024

BUY
$18.21 - $24.5 $1,056 - $1,421
58 Added 30.53%
248 $4,000
Q1 2024

Apr 23, 2024

BUY
$18.65 - $26.52 $1,715 - $2,439
92 Added 93.88%
190 $4,000
Q4 2023

Jan 19, 2024

SELL
$16.53 - $21.42 $2,000 - $2,591
-121 Reduced 55.25%
98 $2,000
Q3 2023

Oct 31, 2023

SELL
$20.08 - $25.39 $220 - $279
-11 Reduced 4.78%
219 $4,000
Q2 2023

Jul 25, 2023

BUY
$24.77 - $29.9 $396 - $478
16 Added 7.48%
230 $5,000
Q1 2023

Apr 24, 2023

BUY
$25.95 - $36.95 $1,634 - $2,327
63 Added 41.72%
214 $5,000
Q2 2022

Aug 04, 2022

BUY
$19.74 - $29.01 $2,980 - $4,380
151 New
151 $4,000
Q1 2022

Apr 19, 2022

SELL
$26.68 - $41.63 $10,085 - $15,736
-378 Closed
0 $0
Q4 2021

Feb 01, 2022

BUY
$33.67 - $43.44 $6,296 - $8,123
187 Added 97.91%
378 $15,000
Q3 2021

Oct 15, 2021

BUY
$30.65 - $35.68 $459 - $535
15 Added 8.52%
191 $6,000
Q2 2021

Aug 06, 2021

SELL
$34.33 - $44.68 $2,197 - $2,859
-64 Reduced 26.67%
176 $6,000
Q4 2020

Feb 16, 2021

BUY
$36.63 - $47.63 $7,326 - $9,526
200 Added 500.0%
240 $10,000
Q3 2020

Nov 09, 2020

BUY
$30.09 - $43.02 $1,203 - $1,720
40 New
40 $2,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.46B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Fifth Third Bancorp Portfolio

Follow Fifth Third Bancorp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Third Bancorp with notifications on news.